These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17675902)

  • 1. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome.
    Sharma AM; Engeli S
    J Cardiometab Syndr; 2006; 1(1):29-35. PubMed ID: 17675902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity, essential hypertension and renin-angiotensin system.
    Segura J; Ruilope LM
    Public Health Nutr; 2007 Oct; 10(10A):1151-5. PubMed ID: 17903324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.
    Putnam K; Shoemaker R; Yiannikouris F; Cassis LA
    Am J Physiol Heart Circ Physiol; 2012 Mar; 302(6):H1219-30. PubMed ID: 22227126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a rationale for angiotensin blockade in the management of obesity hypertension?
    Sharma AM
    Hypertension; 2004 Jul; 44(1):12-9. PubMed ID: 15173127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.
    Jandeleit-Dahm KA; Tikellis C; Reid CM; Johnston CI; Cooper ME
    J Hypertens; 2005 Mar; 23(3):463-73. PubMed ID: 15716683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adipose tissue renin-angiotensin system in obese].
    Yasue S; Ebihara K; Nakao K
    Nihon Rinsho; 2012 Sep; 70(9):1550-5. PubMed ID: 23012802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
    Karalliedde J; Viberti G
    J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome.
    Leung PS; de Gasparo M
    J Cardiometab Syndr; 2006; 1(3):197-203. PubMed ID: 17679833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin system inhibitor and statins combination therapeutics - what have we learnt?
    Koh KK; Sakuma I; Hayashi T; Kim SH; Chung WJ
    Expert Opin Pharmacother; 2015 May; 16(7):949-53. PubMed ID: 25747324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.